Effectiveness of V-Go® for Patients with Type 2 Diabetes in a Real-World Setting: A Prospective Observational Study

Background V-Go is a wearable, patch-like, 24-h insulin delivery device that delivers both a continuous preset basal rate and on-demand bolus dosing. The aim of this study was to observe glycemic control, insulin dosing, and hypoglycemia risk in patients switched to V-Go in a real-world setting. The...

Full description

Saved in:
Bibliographic Details
Published in:Drugs - real world outcomes 2020-03, Vol.7 (1), p.31-40
Main Authors: Grunberger, George, Rosenfeld, Cheryl R., Bode, Bruce W., Abbott, Scott D., Nikkel, Carla, Shi, Leon, Strange, Poul
Format: Article
Language:English
Subjects:
Clinical outcomes
Creatinine
Diabetes
Drug dosages
Effectiveness
Glucose
Hypoglycemia
Insulin
Internal Medicine
Medicine
Medicine & Public Health
NCT
NCT01326598
Observational studies
Original
Original Research Article
Patient satisfaction
Patients
Pharmacology/Toxicology
Pharmacotherapy
Substance abuse treatment
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background V-Go is a wearable, patch-like, 24-h insulin delivery device that delivers both a continuous preset basal rate and on-demand bolus dosing. The aim of this study was to observe glycemic control, insulin dosing, and hypoglycemia risk in patients switched to V-Go in a real-world setting. The primary objective was to compare change in mean hemoglobin A1c (HbA1c) from baseline to the end of V-Go use. Methods This prospective, open-label, multicenter study recruited patients with type 2 diabetes (T2D) and suboptimal glycemic control (HbA1c ≥ 7%) across 28 centers. Efficacy analyses were conducted for all patients with a post-baseline HbA1c and results stratified based on prior antihyperglycemic medication therapies. Insulin dosing was at the discretion of the health care provider and the protocol did not mandate glycemic targets. Treatment satisfaction surveys were utilized to gain patient feedback on the use of V-Go. Results One hundred eighty-eight patients were enrolled in the study, among whom 140 patients had a valid post-baseline HbA1c and were included in the primary efficacy analysis. Use of V-Go resulted in a change of − 0.64%; ( P  = 0.003) in HbA1c from baseline, and in those prescribed insulin, the total daily dose of insulin was decreased by 12 units/day ( P  
ISSN:2199-1154
2198-9788
DOI:10.1007/s40801-019-00173-8